Short Interest in AtriCure Surges 37.3% in February

Medical device company sees significant increase in short positions amid market volatility

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

AtriCure, Inc. (NASDAQ:ATRC), a leading medical device company focused on treatments for atrial fibrillation, saw a significant increase in short interest during the month of February. As of February 13th, short interest totaled 3,447,589 shares, up 37.3% from the previous month's total of 2,510,177 shares. This represents 7.2% of the company's outstanding shares, with the short-interest ratio currently at 3.7 days based on the average daily trading volume.

Why it matters

The surge in short interest for AtriCure reflects broader market volatility and investor uncertainty around the company's performance and outlook. As a medical device maker, AtriCure's business can be impacted by regulatory changes, competition, and broader economic factors. The increase in short positions suggests some investors are betting against the company's near-term prospects, though it's unclear what specific concerns are driving the increased short activity.

The details

The short interest data shows that as of February 13th, there were 3,447,589 shares of AtriCure stock sold short, up from 2,510,177 shares at the end of January. This represents a 37.3% increase in the number of shares being shorted. Based on the company's average daily trading volume of 922,761 shares, the current short-interest ratio stands at 3.7 days, meaning it would take just under 4 days for short sellers to cover their positions at the current pace of trading.

  • As of February 13th, 2026, short interest in AtriCure totaled 3,447,589 shares.
  • On January 29th, 2026, short interest in AtriCure was 2,510,177 shares.

The players

AtriCure, Inc.

A medical device company focused on treatments for atrial fibrillation, headquartered in Mason, Ohio.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest for AtriCure reflects broader market uncertainty, as investors appear to be taking bearish positions on the medical device maker's near-term prospects. However, the company's long-term fundamentals and leadership position in the atrial fibrillation treatment market suggest the increased short activity may be more reflective of short-term volatility than long-term concerns about the business.